Herpes Zoster in the Elderly: An Insight into Prevention
DOI:
https://doi.org/10.14295/idonline.v17i66.3732Keywords:
Vaccine, Elderly, Herpes ZosterAbstract
INTRODUCTION: Infection with Varicella zoster virus causes primary varicella infection. It can reactivate later in life and causes herpes zoster, which mainly occurs in the elderly.This article aimed to review aspects related to the prevention of herpes zoster in older people. METHODS:The study was carried out through a literature review using the keywords “Herpes Zoster”, “Elderly”, “Vaccine” in the MEDLINE, SciELO, BIREME databases, selecting articles published in Portuguese and English for the period from March 2022 to November 2022. Two vaccines are marketed to prevent herpes zoster: the live zoster vaccine and the non- live, recombinant zoster vaccine. Greater efficacy, slower decline in immunity and the possibility of use in immunocompromised patients justify the superiority of non-lived over lived vaccine. CONCLUSION: Herpes Zoster impacts quality of life, causing a reduction in activities of daily living and may lead chronic pain. It is necessary to implement public health policies to ensure the access of older people to the available vaccines and reduce the herpes zoster burden of illness.
Downloads
References
ATTAL, Nadine; MARTINEZ, Valéria; BOUHASSIRA, Didier. Potential for increased prevalence of neuropathic pain after the COVID-19 pandemic. Pain reports, v. 6, n. 1, 2021. DOI: https://doi.org/10.1097/PR9.0000000000000884
CAPUTO, Mahrrouz et al. Herpes zoster incidence in Germany-an indirect validation study for self-reported disease data from pretest studies of the population-based German National Cohort. BMC infectious diseases, v. 19, n. 1, p. 1-8, 2019. DOI: https://doi.org/10.1186/s12879-019-3691-2
COHEN, J. Varicella-zoster virus replication, pathogenesis, and management. Fields virology, v. 2, p. 2773-2818, 2006.
CUNNINGHAM, Anthony L. et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. New England Journal of Medicine, v. 375, n. 11, p. 1019-1032, 2016.
DOOLING, Kathleen L. et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. American Journal of Transplantation, v. 18, n. 3, p. 756-762, 2018. DOI: https://doi.org/10.1111/ajt.14683
DWORKIN, Robert H. et al. Recommendations for the management of herpes zoster. Clinical infectious diseases, v. 44, n. Supplement_1, p. S1-S26, 2007. DOI: https://doi.org/10.1086/510206
ESTATISTICA, Instituto Brasileiro De Geografia. Contingente de idosos residentes no Brasil aumenta 39,8% em 9 anos. Disponivel em: https:// agenciabrasil.ebc.com.br/ geral/noticia/2022-07/contingente-de-idosos-residentes-no-brasil-aumenta-398-em-9-anos. Acesso em: 23 de jan. 2023.
European EudraVigilance Database This Vaccination. Available online: http://www.adrreports.eu. Acesso em: 01 de fev. 2023
GILDEN, Donald H. et al. Neurologic complications of the reactivation of varicella–zoster virus. New England Journal of Medicine, v. 342, n. 9, p. 635-645, 2000. DOI: https://doi.org/10.1056/NEJM200003023420906
GODEAUX, Olivier et al. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults≥ 50 years of age with a prior history of herpes zoster: a phase III, non-randomized, open-label clinical trial. Human vaccines & immunotherapeutics, v. 13, n. 5, p. 1051-1058, 2017. DOI: https://doi.org/10.1080/21645515.2016.1265715
GRINT, Daniel J. et al. Safety of inadvertent administration of live zoster vaccine to immunosuppressed individuals in a UK-based observational cohort analysis. BMJ open, v. 10, n. 1, p. e034886, 2020. DOI: https://doi.org/10.1136/bmjopen-2019-034886
HARBECKE, Ruth; COHEN, Jeffrey I.; OXMAN, Michael N. Herpes zoster vaccines. The Journal of Infectious Diseases, v. 224, n. Supplement_4, p. S429-S442, 2021. DOI: https://doi.org/10.1093/infdis/jiab387
HARPAZ, Rafael; ORTEGA-SANCHEZ, Ismael R.; SEWARD, Jane F. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports, v. 57, n. 5, p. 1-30, 2008.
HEYMANN, Warren R. The herpes zoster vaccine. Journal of the American Academy of Dermatology, v. 58, n. 5, p. 872-873, 2008. DOI: https://doi.org/10.1016/j.jaad.2007.09.013
HOPE-SIMPSON, R. Edgar. The nature of herpes zoster: a long-term study and a new hypothesis. 1965. DOI: https://doi.org/10.1177/003591576505800106
IMUNIZAÇÕES, Sociedade Brasileira. Vacinas Dsponiveis: Vacina Herpes Zoster Atenuada. Disponivel em: https://familia.sbim.org.br/vacinas/vacinas-disponiveis. Acesso em: 14 de fev 2023.
IWANAGA, Joe et al. A narrative review and clinical anatomy of herpes zoster infection following COVID‐19 vaccination. Clinical Anatomy, v. 35, n. 1, p. 45-51, 2022. DOI: https://doi.org/10.1002/ca.23790
JIH, Jaw-Shyang et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta dermato-venereologica, v. 89, n. 6, 2009. DOI: https://doi.org/10.2340/00015555-0729
KAWAI, Kosuke; GEBREMESKEL, Berhanu G.; ACOSTA, Camilo J. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ open, v. 4, n. 6, p. e004833, 2014. DOI: https://doi.org/10.1136/bmjopen-2014-004833
KOSHY, Elsam et al. Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. Indian Journal of Dermatology, Venereology and Leprology, v. 84, p. 251, 2018. DOI: https://doi.org/10.4103/ijdvl.IJDVL_1021_16
KUDESIA, G. et al. Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy. Journal of clinical pathology, v. 55, n. 2, p. 154-155, 2002. DOI: https://doi.org/10.1136/jcp.55.2.154
LAL, Himal et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. New England Journal of Medicine, v. 372, n. 22, p. 2087-2096, 2015. DOI: https://doi.org/10.1056/NEJMoa1501184
LEVIN, Myron J. et al. Studies with herpes zoster vaccines in immune compromised patients. Expert review of vaccines, v. 16, n. 12, p. 1217-1230, 2017. DOI: https://doi.org/10.1080/14760584.2017.1395703
LIAO, Chun-Hui et al. High prevalence of herpes zoster in patients with depression. The Journal of Clinical Psychiatry, v. 76, n. 9, p. 8230, 2015. DOI: https://doi.org/10.4088/JCP.14m09311
MAREQUE, M. et al. Systematic review of the evidence on the epidemiology of herpes zoster: incidence in the general population and specific subpopulations in Spain. Public Health, v. 167, p. 136-146, 2019. DOI: https://doi.org/10.1016/j.puhe.2018.10.015
MOFFAT, Jennifer et al. VZV: pathogenesis and the disease consequences of primary infection. Human herpesviruses: biology, therapy, and immunoprophylaxis, 2007. DOI: https://doi.org/10.1017/CBO9780511545313.038
MOHTA, Alpana et al. Recurrent herpes zoster after COVID‐19 vaccination in patients with chronic urticaria being treated with cyclosporine—A report of 3 cases. Journal of Cosmetic Dermatology, v. 20, n. 11, p. 3384, 2021. DOI: https://doi.org/10.1111/jocd.14437
MORRISON, Vicki A. et al. Long-term persistence of zoster vaccine efficacy. Clinical infectious diseases, v. 60, n. 6, p. 900-909, 2015.
MUNOZ-QUILES, Cintia et al. Risk and impact of herpes zoster on patients with diabetes: a population-based study, 2009–2014. Human vaccines & immunotherapeutics, v. 13, n. 11, p. 2606-2611, 2017. DOI: https://doi.org/10.1080/21645515.2017.1368600
NETO, Lauro; KFOURI, Renato. Nota Técnica – 08/06/2022, Vacina herpes-zóster inativada recombinante (Shingrix®). Sociedade Brasileira de Imunizações. 2022
NIEDERER, Rachel Louise et al. Herpes zoster ophthalmicus clinical presentation and risk factors for loss of vision. American Journal of Ophthalmology, v. 226, p. 83-89, 2021. DOI: https://doi.org/10.1016/j.ajo.2021.02.002
NOFAL, Ahmad et al. Herpes zoster ophthalmicus in COVID‐19 patients. International Journal of Dermatology, v. 59, n. 12, p. 1545, 2020. DOI: https://doi.org/10.1111/ijd.15240
OXMAN, Michael N. et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. New England Journal of Medicine, v. 352, n. 22, p. 2271-2284, 2005.
PONA, Adrian et al. Herpes zoster as a potential complication of coronavirus disease 2019. Dermatologic therapy, v. 33, n. 6, 2020. DOI: https://doi.org/10.1111/dth.13930
RIMLAND, David; MOANNA, Abeer. Increasing incidence of herpes zoster among veterans. Clinical infectious diseases, v. 50, n. 7, p. 1000-1005, 2010. DOI: https://doi.org/10.1086/651078
SCHMADER, K. E. et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clinical infectious diseases, v. 55, n. 10, p. 1320-1328, 2012. DOI: https://doi.org/10.1093/cid/cis638
SCHMADER, Kenneth E. et al. Effect of a Zoster Vaccine on Herpes Zoster–Related Interference with Functional Status and Health‐Related Quality‐of‐Life Measures in Older Adults. Journal of the American Geriatrics Society, v. 58, n. 9, p. 1634-1641, 2010. DOI: https://doi.org/10.1111/j.1532-5415.2010.03021.x
SCHMADER, Kenneth E. et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clinical infectious diseases, v. 54, n. 7, p. 922-928, 2012. DOI: https://doi.org/10.1093/cid/cir970
SYED, Yahiya Y. Recombinant zoster vaccine (Shingrix®): a review in herpes zoster. Drugs & aging, v. 35, p. 1031-1040, 2018. DOI: https://doi.org/10.1007/s40266-018-0603-x
UNIDAS, Nações. World Population Prospects - 2017 Revision: Global population. Disponivel em: https://www.un.org/pt/desa/world-population-prospects-2017-revision-global-population. Acesso em: 15 de fev. 2023.
United States Vaccine Adverse Event Report System (VAERS). Disponivel em: https://wonder.cdc.gov/vaers.html. Acesso em: 13 de fev. 2023.
VAN OORSCHOT, Désirée et al. A systematic literature review of herpes zoster incidence worldwide. Human Vaccines & Immunotherapeutics, v. 17, n. 6, p. 1714-1732, 2021. DOI: https://doi.org/10.1080/21645515.2020.1847582
VARGHESE, Lijoy et al. The temporal impact of aging on the burden of herpes zoster. BMC geriatrics, v. 17, n. 1, p. 1-7, 2017. DOI: https://doi.org/10.1186/s12877-017-0420-9
YAWN, Barbara P. et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. In: Mayo Clinic Proceedings. Elsevier, 2007. p. 1341-1349. DOI: https://doi.org/10.4065/82.11.1341
YU, Ana Lúcia Frugis et al. Three year seroepidemiological study of varicella-zoster virus in São Paulo, Brazil. Revista do Instituto de Medicina Tropical de São Paulo, v. 42, p. 125-128, 2000. DOI: https://doi.org/10.1590/S0036-46652000000300002
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Giulia Ellen Alves de Oliveira, Igor Marcelo Castro e Silva
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Os autores detêm os direitos autorais sem restrições, devendo informar a publicação inicial nesta revista, em caso de nova publicação de algum trabalho.
